ADRA1D
Alpha-1D adrenergic receptor
As of the edition of 20 October 2026, ADRA1D (alpha-1D adrenergic receptor, UniProt P25100) has 40 drugs tested at it and 33 companies on the list, 3 on route A and 12 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25100
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Heart and blood vessels; Urinary and reproductive; Nervous system; Pregnancy and women's health; Lungs and airways; Mental health; Infections; Digestive system
- Registered trials of its drugs
- 1,252
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 34 |
| Active | 2 |
| Went quiet | 2 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 40 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Epinephrine | Marketed | Phase 4 | none listed |
| Norepinephrine | Marketed | Phase 4 | none listed |
| Phenylephrine | Marketed | Phase 4 | none listed |
| Tamsulosin | Marketed | Phase 4 | none listed |
| Carvedilol | Marketed | Phase 4 | none listed |
| Midodrine | Marketed | Phase 4 | none listed |
| Oxymetazoline | Marketed | Phase 4 | none listed |
| Ephedrine | Marketed | Phase 4 | none listed |
| Prazosin | Marketed | Phase 4 | none listed |
| Alfuzosin | Marketed | Phase 4 | none listed |
| Doxazosin | Marketed | Phase 4 | none listed |
| Labetalol | Marketed | Phase 4 | none listed |
12 of 40 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 12 |
| Engaged | 15 |
| Undetermined | 3 |
| Total on the list | 33 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Pfizer | Route B |
| GSK | Route B |
The other 30 companies at ADRA1D
In the product33 companies in all; 30 are not named here, and no score is.
See the 33 companies at ADRA1D, ranked, with the facts behind eachRequest access. Nothing is shown until you do.